Immunovant IMVT
NASDAQ IMVT
$33.62 -0.03 (-0.09%)
At close: Oct 2, 2026 · 4:00 PM EDT

Immunovant (IMVT) Other Accumulated Expenses (2023 - 2026)

Updated

Immunovant's Other Accumulated Expenses came in at $175,000 for fiscal Q4 2026 (quarter ended Mar 31, 2026), down 35.9% from $273,000 a year earlier.

Analysis

Immunovant (IMVT) Other Accumulated Expenses (2023 - 2026) Analysis & Trends

Going back to fiscal Q4 2023, Immunovant's Other Accumulated Expenses data covers 4 quarters.

  • Other Accumulated Expenses carries a three-year compound annual growth rate of -20.6% (FY2023 to FY2026).
  • Going back by fiscal year, Other Accumulated Expenses was $273,000 in FY2025, $15,000 in FY2024 (-95.7%) and $350,000 in FY2023.
  • The fiscal Q4 2026 figure represents the lowest quarterly Other Accumulated Expenses since fiscal Q4 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Immunovant 6.93 Bn 6.93 Bn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 175,000.00
Mar 31, 2025 273,000.00
Mar 31, 2024 15,000.00
Mar 31, 2023 350,000.00
API Access

Immunovant Other Accumulated Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=other-accumulated-expenses&ticker=IMVT&period=max&api_key=YOUR_API_KEY